ATE275417T1 - Verwendung von vegf-c und vegf-d genen oder proteinen zur vorbeugung der restenose - Google Patents

Verwendung von vegf-c und vegf-d genen oder proteinen zur vorbeugung der restenose

Info

Publication number
ATE275417T1
ATE275417T1 AT99956559T AT99956559T ATE275417T1 AT E275417 T1 ATE275417 T1 AT E275417T1 AT 99956559 T AT99956559 T AT 99956559T AT 99956559 T AT99956559 T AT 99956559T AT E275417 T1 ATE275417 T1 AT E275417T1
Authority
AT
Austria
Prior art keywords
vegf
genes
proteins
prevent restenosis
growth factor
Prior art date
Application number
AT99956559T
Other languages
English (en)
Inventor
Yla-Herttuala
Kari Alitalo
Mikko O Hiltunen
Markku M Jeltsch
Marc G Ludwig Achen
Original Assignee
Ludwig Inst Cancer Res
Licentia Ltd
Yla Herttuala Seppo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res, Licentia Ltd, Yla Herttuala Seppo filed Critical Ludwig Inst Cancer Res
Application granted granted Critical
Publication of ATE275417T1 publication Critical patent/ATE275417T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT99956559T 1998-10-26 1999-10-26 Verwendung von vegf-c und vegf-d genen oder proteinen zur vorbeugung der restenose ATE275417T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10558798P 1998-10-26 1998-10-26
PCT/US1999/024054 WO2000024412A2 (en) 1998-10-26 1999-10-26 Use of vegf-c or vegf-d gene or protein to prevent restenosis

Publications (1)

Publication Number Publication Date
ATE275417T1 true ATE275417T1 (de) 2004-09-15

Family

ID=22306672

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99956559T ATE275417T1 (de) 1998-10-26 1999-10-26 Verwendung von vegf-c und vegf-d genen oder proteinen zur vorbeugung der restenose

Country Status (12)

Country Link
EP (1) EP1126870B1 (de)
JP (2) JP4769929B2 (de)
CN (1) CN1338943A (de)
AT (1) ATE275417T1 (de)
AU (1) AU768330B2 (de)
CA (1) CA2340593C (de)
DE (1) DE69920031T2 (de)
ES (1) ES2229788T3 (de)
NO (1) NO20012017L (de)
NZ (1) NZ510121A (de)
PT (1) PT1126870E (de)
WO (1) WO2000024412A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6818220B1 (en) 1994-11-14 2004-11-16 Licentia Ltd. Vascular endothelial growth factor C (VEGF-C) protein and gene mutants thereof, and uses thereof
US7423125B2 (en) 1995-08-01 2008-09-09 Vegenics Limited Antibodies to VEGF-C
US6361946B1 (en) 1997-02-05 2002-03-26 Licentia Ltd Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
US7125714B2 (en) 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
US7223724B1 (en) 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
AU2001239884B2 (en) 2000-02-25 2006-08-10 Vegenics Limited Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins and screening methods for modulators
CA2410901C (en) * 2000-06-01 2012-03-20 University Of North Carolina At Chapel Hill Methods and compounds for controlled release of recombinant parvovirus vectors
TWI257307B (en) 2000-07-12 2006-07-01 Orthologic Corp Pharmaceutical composition for cardiac tissue repair
US7273751B2 (en) 2000-08-04 2007-09-25 Human Genome Science, Inc. Vascular endothelial growth factor-2
AU2002249958B2 (en) * 2001-01-16 2007-11-08 Vascular Therapies, Inc. Implantable device containing resorbable matrix material and anti-proliferative drugs for preventing or treating failure of hemodialysis vascular access and other vascular grafts
DE60236646D1 (de) 2001-04-13 2010-07-22 Human Genome Sciences Inc Anti-VEGF-2 Antikörper
FI20010898A0 (fi) * 2001-04-30 2001-04-30 Ylae Herttuala Seppo Ekstrasellulaarinen superoksididismutaasi (EC-SOD) geeniterapia restenoosoin ehkäisemiseksi
GB0120690D0 (en) 2001-08-24 2001-10-17 Novartis Ag Organic compounds
EP1499344A1 (de) * 2002-04-30 2005-01-26 FIT Biotech Oyj Plc Medizinische vorrichtung
PL195457B1 (pl) * 2002-08-05 2007-09-28 Zaklady Farm Polpharma Sa Kaseta ekspresyjna, dwucistronowy wektor plazmidowy, środek farmaceutyczny oraz ich zastosowanie
US20070254956A1 (en) * 2003-10-29 2007-11-01 Koichi Shudo Medicament for Therapeutic and/or Preventive Treatment of Restenosis or Reocclusion After Vascular Recanalization Operation
US20070077266A1 (en) * 2004-03-18 2007-04-05 Kensuke Egashira Drug/gene eluting stent
WO2007022287A2 (en) 2005-08-15 2007-02-22 Vegenics Limited Modified vegf and pdgf with improved angiogenic properties
CA2663547C (en) 2006-09-22 2020-08-25 Orthologic Corp. Method of treating endothelial dysfunction
US8221738B2 (en) 2008-02-19 2012-07-17 Celladon Corporation Method for enhanced uptake of viral vectors in the myocardium
CN101361988B (zh) * 2008-09-12 2011-12-21 西南交通大学 一种具有生物相容性的血管支架或心脏瓣膜表面涂层的制备方法
WO2012088563A1 (en) * 2010-11-24 2012-07-05 Vegenics Pty Limited Vegfr-2-specific forms of vegf-d and vegf-c and uses thereof
CN108640994A (zh) * 2018-06-28 2018-10-12 浙江众意生物科技有限公司 一种vegf-c单克隆抗体及试剂盒
WO2020205547A1 (en) * 2019-03-29 2020-10-08 Abiomed, Inc. Systems and methods for left ventricular unloading in biologic therapy or vectored gene therapy
CN119454907A (zh) * 2025-01-09 2025-02-18 浙江大学 Vegf-c156s在制备减轻静脉移植物狭窄的药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033917A1 (en) * 1994-11-14 1998-08-06 The Ludwig Institute For Cancer Research Vascular endothelial growth factor c (vegf-c) protein and gene, mutants thereof, and uses thereof
US5830879A (en) * 1995-10-02 1998-11-03 St. Elizabeth's Medical Center Of Boston, Inc. Treatment of vascular injury using vascular endothelial growth factor
CA2263890C (en) * 1996-08-23 2013-05-14 Ludwig Institute For Cancer Research Recombinant vascular endothelial cell growth factor d (vegf-d)
US6013780A (en) * 1996-09-06 2000-01-11 Technion Research & Development Co. Ltd. VEGF145 expression vectors
US5980887A (en) * 1996-11-08 1999-11-09 St. Elizabeth's Medical Center Of Boston Methods for enhancing angiogenesis with endothelial progenitor cells
JP2001524828A (ja) * 1997-04-25 2001-12-04 コラテラル・セラピューティクス 切断型ｖｅｇｆ関連蛋白質

Also Published As

Publication number Publication date
ES2229788T3 (es) 2005-04-16
JP2002528420A (ja) 2002-09-03
JP5231587B2 (ja) 2013-07-10
DE69920031D1 (de) 2004-10-14
JP4769929B2 (ja) 2011-09-07
CA2340593A1 (en) 2000-05-04
AU1314700A (en) 2000-05-15
EP1126870B1 (de) 2004-09-08
WO2000024412A3 (en) 2000-08-03
CA2340593C (en) 2012-05-08
AU768330B2 (en) 2003-12-11
DE69920031T2 (de) 2005-09-22
NZ510121A (en) 2003-02-28
NO20012017L (no) 2001-06-26
PT1126870E (pt) 2005-01-31
JP2011173874A (ja) 2011-09-08
WO2000024412A2 (en) 2000-05-04
CN1338943A (zh) 2002-03-06
NO20012017D0 (no) 2001-04-24
EP1126870A2 (de) 2001-08-29

Similar Documents

Publication Publication Date Title
DE69920031D1 (de) Verwendung von vegf-c und vegf-d genen oder proteinen zur vorbeugung der restenose
DE69827192D1 (de) Stent und Stent-Transplantat zur Behandlung von verzweigten Blutgefässen
DE59611411D1 (de) Verwendung von alpha 1l-agonisten zur behandlung der harninkontinenz
DE69433478D1 (de) Verwendung von stickoxid-addukten zur verhütung von thrombosen auf artifiziellen und vaskulären oberflächen
DE69839060D1 (de) Vegi, ein inhibitor der angiogenese und des tumorwachstums
DE3683318D1 (de) Verwendung von alfuzosin zur behandlung von erkrankungen der harnwege.
ATE271882T1 (de) Supplementierte verdichtungsmittel für gewebe, methoden für ihre herstellung und ihre verwendung
ATE288424T1 (de) Diaminothiazole und ihre verwendung zur inhibierung von proteinkinasen
ATE277034T1 (de) Liponsaürederivate und deren verwendung bei der behandlung von krankheiten
DE69622074D1 (de) Cystin-Silikon-Copolymere und deren Verwendung zur Behandlung von keratinischen Materialien
DE69826847D1 (de) Verwendung von cytoskelettinhibitoren zur vorbeugung der restenose
DE60043229D1 (de) Zusammensetzung zur gefässbeschichtung
DE69941566D1 (de) N-acetylhomotaurinate zur verwendung in der behandlung von hyperkinesie
DE69940206D1 (de) Verfahren zur behandlung von multiplem myelom und von myelom- induzierter knochenresorption mit antagonisten der integrin-/rezeptorbindung
EP1267888A4 (de) Verwendung von niedrigdosierten bisphosphonaten zur verhinderung der verkalkung von herz und arterien
AT388096B (de) Implantat zur befestigung von zahnprothesen
EP1023005A4 (de) Verfahren zum beschichten von stents mit dna sowie zur in vivo expression von rekombinanten genen von mit dna beschichteten
DE69840752D1 (de) Verwendung von coumarine zur behandlung von lebererkrankungen und pankreaserkrankungen
DE68913991D1 (de) Implantat zur verwendung in der knochenchirurgie.
ATE466020T1 (de) Neue isoform des gefässendothelzell wachstumshemmers (vegi)
ATE224731T1 (de) Verwendung von melanomhemmendem faktor zur reparatur von knorpelgewebe und knochen
DE69705936D1 (de) Teil der intronsequenz des von hippel-lindau(vhl)-gens und seine verwendung zur krankheitsdiagnose
DE60017924D1 (de) Rekombinante, adenovirale vektoren und ihre verwendung zur behandlung von leberzirrhose
DE69022776D1 (de) Verwendung von keramischen Materialen als Ersatzmaterialien für lebendes Gewebe.
ATE363072T1 (de) Monoklonaler antikörper gegen mxa und mxb

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1126870

Country of ref document: EP

REN Ceased due to non-payment of the annual fee